Following a decision by the Board of the Association of the British Pharmaceutical Industry (ABPI), the ABPI have issued a new statement on its application for judicial review versus The National Institute for Health and Care Excellence (NICE).
This follows yesterday's confirmation from the Administrative Court that The ABPI's application for judicial review was turned down.
"Following the decision by the Honourable Justice Mrs Elisabeth Laing not to grant the ABPI a judicial review against NICE, the Board of the ABPI has unanimously agreed to accept the decision and will not appeal.
"After months of raising concerns with NICE, NHS England and the Department of Health and offering to work constructively on alternative proposals, the ABPI Board took the exceptional decision in June to apply to the courts to formally challenge new measures introduced by NICE earlier this year for evaluating and funding medicines and other health technologies.
"Our concern has always been that patients should not miss out on medicines which are proven to be both clinically beneficial and cost-effective. Throughout this action the ABPI has maintained positive and constructive dialogue with NICE, the NHS and Government and we are encouraged that the issues are now better understood.
"Working in partnership with industry, Government and the NHS we must now focus on finding real, workable solutions to help NHS patients get fast access to the medicines they need.
"The positive reception by Government to the Life Sciences Industrial Strategy recommendations is a good start and we now look forward to seeing them fully implemented. This is best achieved through agreeing a strong sector deal that both improves access to new medicines and ensures the UK remains a successful place to research and develop medicines."
## ENDS ##
ABPI Press OfficeEmail: email@example.comTelephone: +44 (0)20 7747 7147Mobile: +44 (0)7843 525 553
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.